Wolverine Trading, LLC Rigel Pharmaceuticals Inc Put Options Transaction History

Wolverine Trading, LLC

12 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q4 2021 Feb 14, 2022	SELL	$2.36 - $3.57 $40,356 - $61,047	-17,100 Reduced 61.73%	10,600 $28,000
Q2 2021 Aug 06, 2021	BUY	$3.09 - $4.54 $11,124 - $16,344	3,600 Added 14.94%	27,700 $123,000
Q1 2021 May 14, 2021	BUY	$3.35 - $4.93 $9,045 - $13,311	2,700 Added 12.62%	24,100 $82,000
Q4 2020 Feb 12, 2021	BUY	$2.35 - $3.74 $470 - $748	200 Added 0.94%	21,400 $77,000
Q3 2020 Nov 13, 2020	BUY	$1.78 - $4.13 $17,266 - $40,061	9,700 Added 84.35%	21,200 $49,000
Q2 2020 Aug 13, 2020	BUY	$1.41 - $2.05 $16,214 - $23,574	11,500 New	11,500 $21,000
Q1 2019 May 15, 2019	SELL	$2.0 - $2.65 $74,600 - $98,845	-37,300 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$2.08 - $3.36 $3,952 - $6,384	1,900 Added 5.37%	37,300 $84,000
Q3 2018 Nov 14, 2018	BUY	$2.6 - $3.59 $53,300 - $73,595	20,500 Added 137.58%	35,400 $114,000
Q1 2018 May 15, 2018	BUY	$3.54 - $4.54 $8,496 - $10,896	2,400 Added 19.2%	14,900 $53,000
Q4 2017 Feb 14, 2018	BUY	$3.23 - $4.3 $7,106 - $9,460	2,200 Added 21.36%	12,500 $49,000
Q3 2017 Nov 15, 2017	BUY	$2.18 - $2.57 $22,454 - $26,471	10,300	10,300 $26,000

334K

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $2.96B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Wolverine Trading, LLC with notifications on news.